# Randomized, Double-blind, Multiple-site, Placebo-controlled, Parallel-design Study in Patients With Moderate to Severe Facial Erythema Associated With Rosacea

> **NCT02289352** · PHASE3 · COMPLETED · sponsor: **Actavis Inc.** · enrollment: 462 (actual)

## Conditions studied

- Rosacea

## Interventions

- **DRUG:** Brimonidine
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT02289352
- **Lead sponsor:** Actavis Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 462 (ACTUAL)
- **Last updated:** 2020-01-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02289352

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02289352, "Randomized, Double-blind, Multiple-site, Placebo-controlled, Parallel-design Study in Patients With Moderate to Severe Facial Erythema Associated With Rosacea". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02289352. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*